Vonoprazan

Summary

Vonoprazan (CHEMBL2079130) is an approved small molecule (ATC A02BC08) targeting ATP4A; indicated across 4 conditions including gastroesophageal reflux disease and peptic ulcer disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A02BC08
• Targets: 1 (ATP4A)
• Indications: 4 conditions
• Clinical trials: 108
• Chemistry: 345.4 Da · C17H16FN3O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2079130
Name	Vonoprazan
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	15981397
ATC	A02BC08
Molecular formula	C17H16FN3O2S
Molecular weight	345.4
InChIKey	BFDBKMOZYNOTPK-UHFFFAOYSA-N

SMILES: CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3

IUPAC name: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine

Also known as: TAK-438, Takecab, Vocinti, Vonoprazan, VONOPRAZAN, Vonoprazan Fumarate (TAK-438)

Parent form; salt/anhydrous children: CHEMBL2064032

Patent coverage: 259 distinct patent families (464 SureChEMBL compound mentions), from 4 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ATP4A	ATP4A	Inhibition	7.72	0.2%	P20648

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): ATP4A.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Transport of small molecules	1	ATP4A
Ion transport by P-type ATPases	1	ATP4A
Ion channel transport	1	ATP4A

Dominant GO biological processes

GO term	Targets
intracellular sodium ion homeostasis	1
response to xenobiotic stimulus	1
regulation of proton transport	1
intracellular potassium ion homeostasis	1
monoatomic ion transmembrane transport	1
sodium ion export across plasma membrane	1
pH reduction	1
potassium ion transmembrane transport	1
proton transmembrane transport	1
potassium ion import across plasma membrane	1
monoatomic ion transport	1
potassium ion transport	1
establishment or maintenance of transmembrane electrochemical gradient	1

Indications & clinical

Indications

4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gastroesophageal reflux disease	4	MONDO:0007186	EFO:0003948
peptic ulcer disease	4	MONDO:0004247	HP:0004398
Helicobacter pylori infectious disease	3	MONDO:0006781	EFO:1000961
esophagitis	1	MONDO:0001409	MONDO:0001409

Clinical trials

Total trials: 108.

Phase distribution

Phase	Trials
PHASE3	32
PHASE4	30
PHASE1	21
Not specified	18
PHASE2	4
EARLY_PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05582174	PHASE4	RECRUITING	PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
NCT06168214	PHASE4	RECRUITING	Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication
NCT06526455	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection
NCT06561698	PHASE4	RECRUITING	High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection
NCT06720610	PHASE4	NOT_YET_RECRUITING	Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis
NCT06723197	PHASE4	RECRUITING	Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication
NCT06929962	PHASE4	RECRUITING	VA Dual Sequential Therapy
NCT06959368	PHASE4	RECRUITING	Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication
NCT07040839	PHASE4	NOT_YET_RECRUITING	Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection
NCT07068607	PHASE4	RECRUITING	Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial
NCT02679508	PHASE4	COMPLETED	Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety
NCT03116841	PHASE4	COMPLETED	Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation
NCT03908619	PHASE4	UNKNOWN	A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis
NCT04028466	PHASE4	TERMINATED	Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features
NCT04901663	PHASE4	COMPLETED	Vonoprazan in Helicobacter Pylori Treatment an RCT
NCT04907747	PHASE4	UNKNOWN	Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication
NCT05014334	PHASE4	COMPLETED	Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
NCT05191888	PHASE4	UNKNOWN	14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy
NCT05419674	PHASE4	UNKNOWN	Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection
NCT05469685	PHASE4	COMPLETED	Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication
NCT05590286	PHASE4	UNKNOWN	A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection
NCT05649540	PHASE4	COMPLETED	Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori
NCT05658055	PHASE4	UNKNOWN	The Effect of Probiotics on Gut Microbiotain After Helicobacter Pylori Eradication
NCT05726734	PHASE4	UNKNOWN	Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial
NCT05874544	PHASE4	COMPLETED	Rescue Therapy for Helicobacter Pylori Infection
NCT05901051	PHASE4	COMPLETED	High-dose Dual Therapy with Different Administration Frequencies
NCT06156085	PHASE4	COMPLETED	Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy
NCT06168084	PHASE4	COMPLETED	Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT06514274	PHASE4	COMPLETED	Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication
NCT06561711	PHASE4	COMPLETED	Optimization of Minocycline for Helicobacter Pylori Rescue Treatment
NCT07242456	PHASE2/PHASE3	RECRUITING	Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication
NCT07275827	PHASE3	NOT_YET_RECRUITING	Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection
NCT07608536	PHASE3	NOT_YET_RECRUITING	Comparison of Rabeprazole and Vonoprazan in the Prevention of Post-endoscopic Variceal Ligation Ulcer in Patients With Cirrhosis
NCT01452698	PHASE3	COMPLETED	Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis
NCT01452711	PHASE3	COMPLETED	Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer
NCT01452724	PHASE3	COMPLETED	Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer
NCT01452750	PHASE3	COMPLETED	Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
NCT01452763	PHASE3	COMPLETED	Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
NCT01452776	PHASE3	COMPLETED	Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis
NCT01456247	PHASE3	COMPLETED	Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

5 molecules share ≥1 primary target. Top 5 by shared-target count:

Molecule	Source	Status	Shared targets
CIMETIDINE	ChEMBL + PubChem	Phase 4 (approved)	ATP4A
LANSOPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	ATP4A
PANTOPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	ATP4A
OMEPRAZOLE	ChEMBL	Phase 4 (approved)	ATP4A
RANITIDINE	ChEMBL	Phase 4 (approved)	ATP4A